Literature DB >> 20637583

Relationship between matrix production by bronchial fibroblasts and lung function and AHR in asthma.

Lizbet Todorova1, Leif Bjermer, Anna Miller-Larsson, Gunilla Westergren-Thorsson.   

Abstract

The reasons for enhanced deposition of extracellular matrix in the airways of asthmatic patients and the subsequent consequences on lung function are uncertain. Here, we investigated the synthesis of procollagen I and proteoglycans, the activity of various metalloproteinases (MMPs) and the production of their inhibitor TIMP-1 in biopsy-derived bronchial fibroblasts from eight patients with stable mild-to-moderate asthma, and how they are related to patients' lung function and airway hyperreactivity (AHR). Following 24-h fibroblast incubation in 0.4% serum, procollagen I carboxyterminal propeptide (PICP), TIMP-1 and MMP-1 in cell media were analysed by ELISA, MMP-2, MMP-3, MMP-9 by zymography and total proteoglycan production by [(35)S]-sulphate-incorporation/ion chromatography. Patients' FEV(1)% predicted and methacholine log PD(20) negatively correlated with PICP synthesized by patients' bronchial fibroblasts (r = -0.74 and r = -0.71, respectively). PICP and proteoglycan amounts positively correlated (0.8 ≤ r ≤ 0.9) with MMP-2 and MMP-3 activity. A positive correlation (r = 0.75) was also found between proteoglycan production and TIMP-1. There was no correlation between MMP-9 activity and PICP or proteoglycan production. MMP-9 activity positively correlated with patients' FEV(1)% predicted (r = 0.97) and methacholine log PD(20) (r = 0.86), whereas negative associations (-0.6 ≤ r ≤ -0.7) were observed for MMP-2 and MMP-3. In stable mild-to-moderate asthma, increased procollagen I synthesis and activity of MMP-2 and MMP-3 in bronchial fibroblasts may negatively affect patients' lung function and AHR. In contrast, MMP-9 activity was not associated with procollagen or proteoglycan production, or worsening of patients' lung function and AHR. An enhanced production of procollagen I and proteoglycans might be a result of a negative feedback from their degradation by MMP-2 and MMP-3.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637583     DOI: 10.1016/j.rmed.2010.06.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

Review 1.  Hyaluronan fragments as mediators of inflammation in allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2014-12-31       Impact factor: 3.144

2.  Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease.

Authors:  Minna M Wieck; Ryan G Spurrier; Daniel E Levin; Salvador Garcia Mojica; Michael J Hiatt; Raghava Reddy; Xiaogang Hou; Sonia Navarro; Jooeun Lee; Amber Lundin; Barbara Driscoll; Tracy C Grikscheit
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

3.  Matrix metalloproteinase-1 polymorphism (-1607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan.

Authors:  Meng-Heng Hsieh; Pai-Chien Chou; Chun-Liang Chou; Shu-Chuan Ho; Wen-Ching Joa; Li-Fei Chen; Te-Fang Sheng; Horng-Chyuan Lin; Tsai-Yu Wang; Po-Jui Chang; Chun-Hua Wang; Han-Pin Kuo
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

4.  Increased Ratio of Matrix Metalloproteinase-9 (MMP-9)/Tissue Inhibitor Metalloproteinase-1 from Alveolar Macrophages in Chronic Asthma with a Fast Decline in FEV1 at 5-Year Follow-up.

Authors:  Fu-Tsai Chung; Hung-Yu Huang; Chun-Yu Lo; Yu-Chen Huang; Chang-Wei Lin; Chih-Chen He; Jung-Ru He; Te-Fang Sheng; Chun-Hua Wang
Journal:  J Clin Med       Date:  2019-09-12       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.